secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001082554-23-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q1 revenue $506.9M (+10% YoY); Tyvaso sales up 39%
----------------------------------------------------------------------

- Net income $240.9M flat YoY; diluted EPS $4.86 vs $5.03.
- Tyvaso franchise net sales $238.4M (+39%) driven by Tyvaso DPI launch and label expansion.
- Treprostinil products grew 16% combined; Orenitram hit record revenue of $88.2M.
- R&D expense rose 20% to $82.9M, primarily on TETON IPF studies.
- Effective tax rate decreased to 17% from 22% due to excess share-based compensation benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255423000014/0001082554-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255423000014/uthr-20230503.htm
  HTML page:      https://secwatch.observer/filing/0001082554-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer